cover
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
japr.editor@gmail.com
Editorial Address
Plot No. 105/42, Opposite electricity sub station, Changorabhata, Raipur (Chhattisgarh), India 492001
Location
,
INDONESIA
Journal of Applied Pharmaceutical Research
Published by Creative Pharma Assent
ISSN : -     EISSN : 23480335     DOI : 10.18231
Core Subject : Health,
Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
Arjuna Subject : -
Articles 533 Documents
Development and optimization of amorphous dry powder formulation of bilastine for pulmonary delivery using lyophilization technique Sheetal Z. Godse; Avinash B. Gangurde; Rahul Y. Pagar
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2594

Abstract

Background: Conventional treatments for pulmonary diseases like asthma and chronic obstructive pulmonary disease (COPD) often lack rapid, targeted action. To address this, direct pulmonary drug delivery is preferred because it offers faster onset, greater efficacy, and fewer systemic side effects. Dry Powder Inhalers (DPIs) have emerged as the optimal choice because they are stable, portable, easy to use, and propellant-free. Methodology: We prepared bilastine DPIs by lyophilization from an ethanol:water solution containing Soluplus (20-30% w/w), mannitol (30-40% w/w), and L-leucine (5-15% w/w) as key excipients. We employed a Box-Behnken experimental design with 17 formulations to systematically optimize fine particle fraction, mass median aerodynamic diameter, and amorphicity index. We performed XRD, SEM, FTIR, DSC, flow characterization, and aerodynamic performance assessment using the Next Generation Impactor. We used goat pulmonary tissue in ex vivo diffusion studies. Results and Discussion: The F12 batch was optimal because it had a higher FPF (44.1%), good flow characteristics (Carr's index: 12.8%), an optimal MMAD (3.86 µm), and a suitable amorphicity index (0.65). Ex vivo research showed cumulative diffusion of 86.2%, compared with 22.6% for crystalline drugs. Conclusion: The optimized amorphous bilastine dry powder inhaler (DPI) demonstrated improved aerodynamic performance and pulmonary drug delivery. We attribute enhanced ex vivo drug diffusion to reduced particle size, improved surface properties, increased dispersibility, and efficient carrier-assisted deposition. These characteristics contributed to greater fine particle generation and enhanced pulmonary permeation. The findings suggest that the lyophilization-based amorphous formulation is a promising strategy for improving pulmonary drug delivery. However, further in vivo studies are required to confirm its therapeutic efficacy and clinical potential.
Advanced respiratory drug delivery systems from nanocarriers to intelligent inhalation technologies: revolutionizing pulmonary therapeutics Gargi Sawant; Archana Barhate
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2599

Abstract

Background: Respiratory drug delivery systems (RDDS) are important for treating respiratory and systemic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Pulmonary administration offers rapid drug action, targeted delivery, and avoidance of first-pass metabolism. Methodology: This review examines recent developments in RDDS, emphasizing nanotechnology-based systems such as liposomes, solid lipid nanoparticles (SLNs), and polymeric nanoparticles. The review also discusses conventional inhalation devices, including nebulizers, dry powder inhalers (DPIs), and metered-dose inhalers (MDIs). The review covers key factors affecting delivery, including particle size, aerosol dynamics, device design, mucociliary clearance, and enzymatic degradation. The authors also consider formulation and manufacturing approaches such as micronization and spray drying. Results and Discussion: Nanotechnology-based carriers offer potential advantages, including sustained drug release and improved pulmonary delivery. RDDS have applications in respiratory and infectious diseases, lung cancer, pulmonary hypertension, and inhaled vaccines and gene therapy. The review also highlights challenges related to formulation development, manufacturing, inhalation systems, and patient inhalation technique. Effective pulmonary delivery depends on appropriate formulation characteristics, aerosol behavior, device performance, and physiological conditions. These factors can influence drug deposition and therapeutic effectiveness. Conclusion: Advances in nanocarrier-based and inhalation technologies are expanding the potential of pulmonary therapeutics. Further development of effective formulations, scalable manufacturing methods, and patient-friendly inhalation systems may support improved pulmonary drug delivery.
QbD-based formulation, development and characterization of methotrexate-loaded nanoemulgel for transdermal administration in rheumatoid arthritis: preclinical studies Neha Gupta; Mamta Bishnoi; Shaik Abdul Rahaman
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2784

Abstract

Background: Rheumatoid arthritis is an autoimmune inflammatory disease with a chronic relapsing course, and usually lifelong treatment is necessary. Methotrexate, the first-line drug, has poor bioavailability and systemic toxicity after conventional routes of administration. Methodology: They were characterized for particle size, polydispersity index, zeta potential, entrapment efficiency, and percentage transmittance prior to incorporation into Carbopol Ultrez 10 NF gel. MTX-NEG was characterized for physicochemical profiles, in vitro drug release, ex vivo permeation, and pharmacodynamic efficacy in carrageenan-induced paw edema and formaldehyde-induced arthritis models. Result and discussion: The optimized MTX-loaded nanoemulsion showed droplet size of 124.31±0.69 nm, PDI of 0.164±0.01, zeta potential of -28.6±3.9 mV, entrapment efficiency of 85.46±1.24%, and transmittance factor of 98.63±0.95 % which have demonstrated the stability as well as homogeneity of formulations indicated good formulation characteristics for long duration study with distinct advantages over conventional carriers packaged inside micellar aggregates in aqueous. Results: Suitable topical pH, viscosity, and spreadability were achieved with MTX-NEG. In vitro release studies exhibited prolongation of drug release (82.35±0.97% over 48 h) as compared to conventional gel formulations. With ex vivo studies, membrane permeation and skin retention were confirmed. The pharmacodynamic study showed that nanocarriers could significantly inhibit (p < 0.05) paw edema and joint swelling compared to both conventional gel formulations and marketed gels. Conclusion: Physicochemical properties, prolonged drug release, increased membrane permeation, and anti-inflammatory and anti-arthritic efficacy. This nano-mulgel system has shown potential as a topical delivery system for rheumatoid arthritis management.

Filter by Year

2013 2026


Filter By Issues
All Issue Vol. 14 No. 5 (2026) Vol. 14 No. 4 (2026) Vol. 14 No. 3 (2026) Vol. 13 No. 4 (2025) Vol. 13 No. 3 (2025) Vol. 13 No. 2 (2025) Vol. 13 No. 1 (2025) Vol. 12 No. 6 (2024) Vol. 12 No. 5 (2024) Vol. 12 No. 4 (2024) Vol. 12 No. 3 (2024) Vol. 12 No. 2 (2024) Vol. 12 No. 1 (2024) Vol. 11 No. 5 (2023) Vol. 11 No. 4 (2023) Vol. 11 No. 3 (2023) Vol. 11 No. 2 (2023) Vol. 11 No. 1 (2023) Vol. 10 No. 4 (2022) Vol. 10 No. 3 (2022) Vol. 10 No. 2 (2022) Vol. 10 No. 1 (2022) Vol. 9 No. 4 (2021) Vol. 9 No. 3 (2021) Vol. 9 No. 2 (2021) Vol. 9 No. 1 (2021) Vol. 8 No. 4 (2020) Vol. 8 No. 3 (2020) Vol. 8 No. 2 (2020) Vol. 8 No. 1 (2020) Vol. 7 No. 4 (2019) Vol 7 No 3 (2019) Vol. 7 No. 3 (2019) Vol 7 No 2 (2019) Vol. 7 No. 2 (2019) Vol 7 No 1 (2019) Vol. 7 No. 1 (2019) Vol 6 No 4 (2018) Vol. 6 No. 4 (2018) Vol 6 No 3 (2018) Vol. 6 No. 3 (2018) Vol 6 No 2 (2018) Vol. 6 No. 2 (2018) Vol 6 No 1 (2018) Vol. 6 No. 1 (2018) Vol. 5 No. 4 (2017) Vol 5 No 4 (2017) Vol 5 No 3 (2017) Vol. 5 No. 3 (2017) Vol 5 No 2 (2017) Vol. 5 No. 2 (2017) Vol. 5 No. 1 (2017) Vol 5 No 1 (2017) Vol 4 No 4 (2016) Vol. 4 No. 4 (2016) Vol 4 No 3 (2016) Vol. 4 No. 3 (2016) Vol. 4 No. 2 (2016) Vol 4 No 2 (2016) Vol. 4 No. 1 (2016) Vol 4 No 1 (2016) Vol 3 No 4 (2015) Vol. 3 No. 4 (2015) Vol. 3 No. 3 (2015) Vol 3 No 3 (2015) Vol 3 No 2 (2015) Vol. 3 No. 2 (2015) Vol. 3 No. 1 (2015) Vol 3 No 1 (2015) Vol 2 No 4 (2014) Vol. 2 No. 4 (2014) Vol 2 No 3 (2014) Vol. 2 No. 3 (2014) Vol. 2 No. 2 (2014) Vol 2 No 2 (2014) Vol. 2 No. 1 (2014) Vol 2 No 1 (2014) Vol. 1 No. 1 (2013) Vol 1 No 1 (2013) More Issue